Raymonde Busch integrates Endocrinology and Physiology in her research. In her papers, she integrates diverse fields, such as Physiology and Endocrinology. In her study, she carries out multidisciplinary Hormone and Prostaglandin research. She carries out multidisciplinary research, doing studies in Prostaglandin and Hormone. Raymonde Busch regularly links together related areas like Hair follicle in her Internal medicine studies. Raymonde Busch performs integrative Follicular phase and Corpus luteum research in her work. Raymonde Busch combines Corpus luteum and Estrous cycle in her research. While working on this project, she studies both Estrous cycle and Luteal phase. She combines Luteal phase and Luteolysis in her research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink.
The Lancet (2010)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke.
The New England Journal of Medicine (2014)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold.
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
Wolfgang A. Weber;Katja Ott;Karen Becker;Hans-Joachim Dittler.
Journal of Clinical Oncology (2001)
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.
Karen Becker;James D. Mueller;Christoph Schulmacher;Katja Ott.
Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.
Erika Rosivatz;Ingrid Becker;Katja Specht;Elena Fricke.
American Journal of Pathology (2002)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz;Barbara Eichhorst;Raymonde Busch;Tina Denzel.
Journal of Clinical Oncology (2010)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Barbara Eichhorst;Anna-Maria Fink;Jasmin Bahlo;Raymonde Busch.
Lancet Oncology (2016)
Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group.
Siewert;Böttcher K;Roder Jd;Busch R.
British Journal of Surgery (1993)
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Sebastian Böttcher;Matthias Ritgen;Kirsten Fischer;Stephan Stilgenbauer.
Journal of Clinical Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: